SecBot SecBot
8-K ·Filed Nov 3, 2026

RARE

Ultragenyx Pharmaceutical Inc.
MIXED
Impact 6/10
Horizonmonths Processed13d 11h ago SEC0001193125-26-445342
Killer combo: Earnings + restructuring announcement
Actionable Insight ◆ Mixed

Monitor closing of the second PRV sale ($203M) expected this month and Q4 2025 results for restructuring charge impact and initial GENGLYCOS/FAYUVI launch revenue. The path to 2027 GAAP profitability depends on successful commercialization of two new gene therapies and sustained cost discipline.

DirectionMixed
Confidencehigh
Horizonmonths

Drugs in focus

RARE drug pipeline →

Evkeeza

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
Next catalyst
None dated

What to watchEvkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.

Price Chart

Loading chart...

Executive Summary

Ultragenyx completed the sale of a Rare Pediatric Disease PRV for $210M in gross proceeds (net ~$168M after NIH share), reported Q3 2026 total revenue of $173M (up 8% YoY from $160M) with a net loss of $118M ($1.16 per share) vs $180M loss a year ago, and announced a restructuring plan cutting ~20% of employees with ~$25M in charges. The PRV sale provides non-dilutive cash, but the restructuring signals cost pressure as the company transitions to commercial stage after two gene therapy approvals.

Key Financial Metrics

EPS
−$1.16
est −$0.75 · -54.7%
Revenue
$173.0M
est $183.7M · -5.8% · +8.1% YoY
Rating
miss
Guidance
$730M-$760M
maintained

Key Facts

  • Completed sale of GENGLYCOS PRV for $210M gross proceeds on October 30, 2026; 20% ($42M) payable to NIH, net ~$168M
  • Q3 2026 total revenue $173M vs $160M YoY (up 8%); CRYSVITA $109M, DOJOLVI $30M, EVKEEZA $24M, MEPSEVII $10M
  • Q3 2026 net loss $118M ($1.16 per share) vs $180M ($1.81) YoY; operating expenses $283M vs $331M
  • Cash and marketable securities $401M as of Sep 30, 2026, down from $737M at Dec 31, 2025
  • Restructuring plan: 20% workforce reduction, ~$25M in charges expected in Q4 2026, wind-down of GTX-102 (Angelman) and termination of UX701 (Wilson)
  • Reaffirmed 2026 revenue guidance $730M-$760M (excl. new launches) and full-year GAAP profitability in 2027
  • Second PRV (FAYUVI) under agreement for $203M expected to close later in November 2026
  • R&D expenses cut 29% YoY to $154M in Q3; 2027 R&D guided to <$350M, SG&A <$375M

Financial Impact

PRV sale provides ~$350M net cash from two vouchers; restructuring targets at least 50% reduction in 2027 R&D vs 2025; Q3 revenue grew 8% YoY but cash burn remains significant

revenuecashoperating expensesheadcount

Segment Breakdown

SegmentRevenueGrowth
CRYSVITA$109.0M-2.7%
DOJOLVI$30.0M+25.0%
EVKEEZA$24.0M+41.2%
MEPSEVII$10.0M+42.9%

Risk Factors

  • Cash burn: cash dropped from $737M to $401M over nine months despite no major M&A; PRV proceeds are one-time
  • Restructuring execution risk: 20% headcount reduction may disrupt commercial launches and R&D pipeline
  • GENGLYCOS accelerated approval requires confirmatory studies; failure could lead to withdrawal
  • GTX-102 (Angelman) wind-down and UX701 termination reduce pipeline optionality
  • Stockholders' deficit grew to $376M from $80M at year-end 2025

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-445342
Document: 0001193125-26-445342-index.html0001193125-26-445342
Document: 0001193125-26-445342.txt0001193125-26-445342
8-K Data (Synthetic)0001193125-26-445342

Track record

22 reports on RARE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 Viewing No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 5h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026